NSF TraQtion Powers Novozymes’ Raw Material Management in Industry First

Novozymes has successfully implemented NSF TraQtion for managing raw material quality and continuously improve compliance for the production of enzymes and proteins across several industries

NSF, a leading global public health and safety organization, is pleased to announce that Novozymes, a leader in biosolutions, has become the world’s first company to implement NSF TraQtion software for managing the quality and compliance of raw materials used in the production of enzymes and proteins serving multiple industries.

NSF TraQtion is a cloud-based quality and compliance software that provides organizations with a comprehensive platform to proactively manage their supply chain, sites, and product quality. NSF TraQtion was initially developed to help customers maintain a higher level of food safety and quality compliance. Its implementation by Novozymes demonstrates the versatility of the software across diverse industries, offering timely and insightful information for making informed decisions.

As an industry pioneer in risk management and mitigation solutions, NSF has a proven track record of ensuring product safety, quality, and compliance across various sectors, including food and health science. In today’s increasingly complex supply chains, risks stemming from globalization, extreme weather events, geopolitical influences, and persistent raw material inflation highlight the need for more robust supply chain management solutions.

Matthew Allen, Senior Director, Food & Sustainability Advisory Solutions at NSF……

“We are delighted to have Novozymes as a client utilizing NSF TraQtion. This achievement showcases the versatility and effectiveness of NSF TraQtion digital solutions across diverse industries. With our extensive expertise and deep understanding of global supply chain dynamics, we are confident in our ability to support Novozymes in enhancing their raw material management process.”

Novozymes is also exploring applications of NSF TraQtion within dietary supplements and health sciences in the future, marking the start of NSF TraQtion’s expansion into these sectors.

NSF TraQtion software offers comprehensive data management and business intelligence capabilities. It combines decades of industry expertise with real-time digital insights in a trusted, cloud-based solution that provides businesses with the assurance they need to confidently manage complex and critical data – including supplier compliance, regulatory requirements, and environmental reporting.

“The adoption of NSF TraQtion by Novozymes underscores NSF’s commitment to delivering cutting-edge solutions to address emerging challenges across industries. By harnessing advanced technologies and industry expertise, NSF TraQtion empowers organizations to proactively manage risk, ensure compliance and product quality, and fortify the overall resilience of their supply chains in a single, secure platform,” stated David Lonza, Vice President, Health Sciences, NSF.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

OCSiAl’s exceptional graphene nanotubes -based solution addresses these issues, ushering in a new era of silicone PSA technology. The user-friendly nanotube dispersion TUBALLTM MATRIX 617 results in excellent electrical conductivity combined with more than 90% transparency in a wide range of peeling-strength PSA films.
“Our latest study is the result of six years of focused research, delivering a practical model that allows users to predict metabolic pathways for a wide range of drug-like compounds. Thanks to our carefully curated datasets and our signature reactivity-accessibility approach, we have managed to build accurate isoform-specific regioselectivity models for the important Phase I and II enzyme families” Dr Mario Öeren, Principal Scientist, Optibrium said
The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks.
"We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation. We believe Lycia's leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences said.
Through this named patient program in the Netherlands ('Leveren op Artsenverklaring'), physicians may seek individual access to TLX250-CDx for use in PET characterisation of renal masses as ccRCC. The first patient was dosed at Radboud University Medical Centre in Nijmegen, Netherlands.

By using this website you agree to accept Medical Device News Magazine Privacy Policy